Market capitalization | $54.93m |
Enterprise Value | $-111.02m |
P/E (TTM) P/E ratio | negative |
EV/FCF (TTM) EV/FCF | 0.79 |
P/B ratio (TTM) P/B ratio | 0.32 |
Revenue (TTM) Revenue | $0.00 |
EBIT (operating result TTM) EBIT | $-160.92m |
Free Cash Flow (TTM) Free Cash Flow | $-140.75m |
Cash position | $175.50m |
As a Free StocksGuide user, you can view scores for all 6,886 stocks worldwide.
4 Analysts have issued a Mural Oncology forecast:
4 Analysts have issued a Mural Oncology forecast:
Sep '24 |
+/-
%
|
||
Revenue | - - |
-
|
|
Gross Profit | -3.26 -3.26 |
-
|
|
EBITDA | -158 -158 |
-
|
EBIT (Operating Income) EBIT | -161 -161 |
-
|
Net Profit | -154 -154 |
-
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Mural Oncology Plc operates as a clinical stage company. It focus on discovering and developing immuno therapies that may meaningfully improve the lives of patients with cancer. Its portfolio of novel, investigational cytokine therapies designed to address areas of unmet need for patients with a variety of cancers. The company was founded in May 2017 and is headquartered in Dublin, Ireland.
Head office | Ireland |
CEO | Caroline Loew |
Employees | 117 |
Founded | 2017 |
Website | www.muraloncology.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.